Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide

Completed · Phase 2

Conditions studied: Multiple Myeloma

In brief

The purpose of this research is to study how helpful the combination of thalidomide and Pamidronate or thalidomide and Zometa is in controlling the myeloma disease and to study any side effects.

Key facts

Study ID

NCT00083382

Run by

University of Arkansas

People needed

83

Starts

1998-12-01

Expected to finish

2014-05-01

Last updated by the study team

2015-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have a diagnosis of Smoldering or Indolent myeloma
• All patients must be informed of the investigational nature of this study and must sign a written informed consent in accordance with UAMS Human Research Advisory Committee and federal guidelines.

You may not qualify if…

• Prior bisphosphonate therapy within 30 days prior to study entry.
• Serum creatinine > 5 mg/dl, ascites, or serum direct bilirubin > 2.5 mg/dl.
• Prior plicamycin or calcitonin within 2 weeks of study entry.
• Severe cardiac disease, unstable thyroid disease, or epilepsy.
• Prior radiation therapy to > 20% of the skeleton.

Where it is running

• University of Arkansas for Medical Sciences/MIRT — Little Rock, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.